Arvinas appoints new president, CEO
This article was originally published in Scrip
Executive Summary
New Haven, Connecticut-based Arvinas, a biotechnology company creating a new class of oncology drugs based on protein degradation, has appointed Dr Manuel Litchman president and CEO of the company. Dr Litchman was most recently senior vice-president and global program head at Novartis Pharmaceuticals.
You may also be interested in...
Rising From The Ashes Of 2020: ‘We Must Not Waste The Learning,’ Says Dame Sally
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
In Vivo’s Deals Of The Year 2020: Cast Your Vote!
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Deals Shaping The Medical Industry, December 2020
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.
Need a specific report? 1000+ reports available
Buy Reports